JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell l

[News]

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

More... (http://www.news-medical.net/news/20120430/JCO-publishes-Syndax-erlotinib-entinostat-Phase-2-study-for-advanced-non-small-cell-lung-cancer.aspx)